Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Non Operating Income (2024 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Non Operating Income for 4 consecutive years, with -$21000.0 as the latest value for Q4 2025.

  • For Q4 2025, Non Operating Income fell 101.12% year-over-year to -$21000.0; the TTM value through Dec 2025 reached -$3.6 million, down 181.95%, while the annual FY2025 figure was -$3.6 million, 181.95% down from the prior year.
  • Non Operating Income hit -$21000.0 in Q4 2025 for Sangamo Therapeutics, down from $107000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $2.1 million in Q1 2024 and bottomed at -$2.5 million in Q2 2025.